The estimated Net Worth of Francesco Maria Lavino is at least $1.36 Million dollars as of 19 August 2020. Mr. Lavino owns over 11,250 units of Nabriva Therapeutics Plc stock worth over $269,635 and over the last 7 years he sold NBRV stock worth over $0. In addition, he makes $1,088,760 as Chief Commercial Officer at Nabriva Therapeutics Plc.
Sign up
Mr. Lavino NBRV stock SEC Form 4 insiders trading
Francesco has made over 5 trades of the Nabriva Therapeutics Plc stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 11,250 units of NBRV stock worth $15,975 on 19 August 2020.
The largest trade he's ever made was exercising 11,250 units of Nabriva Therapeutics Plc stock on 19 August 2020 worth over $15,975. On average, Francesco trades about 1,724 units every 55 days since 2017. As of 19 August 2020 he still owns at least 189,884 units of Nabriva Therapeutics Plc stock.
You can see the complete history of Mr. Lavino stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Francesco Lavino biography
Francesco Maria Lavino serves as Chief Commercial Officer of the Company. Previously, Mr. Lavino served as associate vice president and global brand leader for the anti-infective portfolio at Merck & Co. from September 2015 to July 2017. Prior to Merck, Mr. Lavino was vice president of international marketing for Cubist Pharmaceuticals from December 2013 until September 2015. Before joining Cubist, Mr. Lavino spent 10 years with Merck & Co. in various roles, including serving as executive director and global brand leader for Merck's anti-fungal portfolio from January 2011 to November 2013. Mr. Lavino began his career in pharmaceutical sales at UCB S.A. and 3M Company in Italy. He has a B.A. in Pharmacy from the Federico II University of Napoli, Italy and an M.B.A. from SDA Bocconi School of Management in Milan, Italy.
What is the salary of Francesco Lavino?
As the Chief Commercial Officer of Nabriva Therapeutics Plc, the total compensation of Francesco Lavino at Nabriva Therapeutics Plc is $1,088,760. There are 3 executives at Nabriva Therapeutics Plc getting paid more, with Colin Broom having the highest compensation of $2,044,990.
How old is Francesco Lavino?
Francesco Lavino is 47, he's been the Chief Commercial Officer of Nabriva Therapeutics Plc since 2017. There are 15 older and 2 younger executives at Nabriva Therapeutics Plc. The oldest executive at Nabriva Therapeutics Plc is George Talbot, 72, who is the Independent member of the Supervisory Board.
What's Francesco Lavino's mailing address?
Francesco's mailing address filed with the SEC is 1000 Continental Dr #600, King of Prussia, PA 19406, USA.
Insiders trading at Nabriva Therapeutics Plc
Over the last 8 years, insiders at Nabriva Therapeutics Plc have traded over $3,221,169 worth of Nabriva Therapeutics Plc stock and bought 436,925 units worth $1,215,585 . The most active insiders traders include Capital Viii, Llc Vivo, Bioventures Cayman Ltd Hbm und Charles A Jr Rowland. On average, Nabriva Therapeutics Plc executives and independent directors trade stock every 33 days with the average trade being worth of $23,562. The most recent stock trade was executed by Daniel D Burgess on 2 August 2022, trading 11,341 units of NBRV stock currently worth $2,155.
What does Nabriva Therapeutics Plc do?
nabriva is a clinical-stage biopharmaceutical company engaged in the research and development of novel antibiotics to treat serious infections, with a focus on the pleuromutilin class of antibiotics. our goal is to become a fully integrated biopharmaceutical company focused on the research, development and commercialization of novel anti-infective products. nabriva was incorporated as a spin-off from sandoz gmbh antibiotics research institute (abri) in vienna, austria and commenced operations in february 2006. the new organization included small molecule assets, including pleuromutilin structure activity relationships (sar) knowledge and was focused on synthesis of pleuromutilins for systemic human use. following identification of our lead compound lefamulin and based on the clinical results of lefamulin for acute skin and skin structure infections. we believed that targeted in vitro spectrum of activity for the common pathogens causing community acquired bacterial pneumonia (cabp), wo
What does Nabriva Therapeutics Plc's logo look like?
Complete history of Mr. Lavino stock trades at Nabriva Therapeutics Plc
Nabriva Therapeutics Plc executives and stock owners
Nabriva Therapeutics Plc executives and other stock owners filed with the SEC include:
-
Colin Broom,
Director -
Theodore Schroeder,
Chief Executive Officer, Director -
Steven Gelone,
President, Chief Operating Officer -
Francesco Lavino,
Chief Commercial Officer -
Gary Sender,
Chief Financial Officer -
Jennifer Schranz,
Chief Medical Officer -
Theodore R. Schroeder,
CEO & Director -
Dr. Steven P. Gelone Pharm. D,
Pres, COO & Director -
Dr. Colin Broom M.D.,
Director -
Stephen Webster,
Independent Member of the Supervisory Board -
George Talbot,
Independent member of the Supervisory Board -
Charles Rowland,
Independent Member of the Supervisory Board -
Carrie Bourdow,
Independent Member of the Supervisory Board -
Robert Crotty,
General Counsel, Secretary -
Daniel Burgess,
Independent Chairman of the Supervisory Board -
Werner Heilmayer,
VP of CMC & IP -
Dr. Christine J. Guico-Pabia M.B.A., M.D., M.P.H.,
Chief Medical Officer -
Gary L. Sender,
Consultant -
Jodi VanDerveer,
Sr. VP & Head of HR -
J. Christopher Naftzger BA, Esq., J.D.,
Gen. Counsel -
Daniel Dolan,
Chief Financial Officer -
Bioventures Cayman Ltd Hbm,
10% owner -
Elyse G. Seltzer,
Chief Medical Officer -
J. Christopher Naftzger,
General Counsel and Corp Sec -
Capital Viii, Llc Vivo,
10% owner -
Mark Corrigan,
Director -
Christine J. Guico Pabia,
Chief Medical Officer -
Daniel Dolan,
Chief Financial Officer -
Lisa Dalton,
Director